Targeting breast cancer stem cells

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 4006-4012

  Liu, Suling ^a   Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERIFOSINE; REPARIXIN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL RENEWAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; ANIMAL; BREAST TUMOR; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

EID: 77957591579     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.5388     Document Type: Review

References (59)

1. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005 (Pubitemid 41549890)
2. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988, 2003 (Pubitemid 36418143)
4. Ginestier C, Hur MH, Charafe-Jauffret E, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567, 2007 (Pubitemid 350056407)
5. Charafe-Jauffret E, Ginestier C, Iovino F, et al: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69:1302-1313, 2009
6. Wright MH, Calcagno AM, Salcido CD, et al: Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:R10, 2008
7. Dontu G, El-Ashry D, Wicha MS: Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197, 2004 (Pubitemid 38833988)
8. Dontu G, Abdallah WM, Foley JM, et al: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-1270, 2003
9. Shackleton M, Vaillant F, Simpson KJ, et al: Generation of a functional mammary gland from a single stem cell. Nature 439:84-88, 2006 (Pubitemid 43053633)
10. Mulholland DJ, Xin L, Morim A, et al: Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69:8555-8562, 2009
11. Dave B, Chang J: Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14:79-82, 2009
12. Woodward WA, Chen MS, Behbod F, et al: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104:618-623, 2007 (Pubitemid 46123074)
13. Li X, Lewis MT, Huang J, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679, 2008
14. Creighton CJ, Li X, Landis M, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820-13825, 2009
15. Horwitz KB, Dye WW, Harrell JC, et al: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 105:5774-5779, 2008 (Pubitemid 351758448)
16. Asselin-Labat ML, Shackleton M, Stingl J, et al: Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 98:1011-1014, 2006 (Pubitemid 44288166)
17. Engelmann K, Shen H, Finn OJ: MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 68:2419-2426, 2008 (Pubitemid 351521817)
18. Mirkes PE, Ellison A, Little SA: Role of aldehyde dehydrogenase (ALDH) in the detoxication of cyclophosphamide (CP) in rat embryos. Adv Exp Med Biol 284:85-95, 1991
19. Wang S, Yang D, Lippman ME: Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 30:133-142, 2003 (Pubitemid 37433404)
20. Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7:989-999, 2009
21. Vorechovský I, Benediktsson KP, Toftgård R: The patched/hedgehog/smoothened signalling pathway in human breast cancer: No evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer 35:711-713, 1999
22. Soriano JV, Uyttendaele H, Kitajewski J, et al: Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer 86:652-659, 2000 (Pubitemid 30249875)
23. Kelly OG, Pinson KI, Skarnes WC: The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development 131:2803-2815, 2004 (Pubitemid 39004073)
24. Huelsken J, Vogel R, Brinkmann V, et al: Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol 148:567-578, 2000
25. Pasca di Magliano M, Hebrok M: Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903-911, 2003
26. Karhadkar SS, Bova GS, Abdallah N, et al: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431:707-712, 2004 (Pubitemid 39382619)
27. Liu S, Dontu G, Wicha MS: Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7:86-95, 2005 (Pubitemid 40704127)
28. Korkaya H, Wicha MS: Selective targeting of cancer stem cells: A new concept in cancer therapeutics. BioDrugs 21:299-310, 2007 (Pubitemid 47529469)
29. Uyttendaele H, Soriano JV, Montesano R, et al: Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol 196:204-217, 1998 (Pubitemid 28198847)
30. Milano J, McKay J, Dagenais C, et al: Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82:341-358, 2004 (Pubitemid 39485346)
31. Real PJ, Ferrando AA: NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 23:1374-1377, 2009
32. Tian H, Callahan CA, DuPree KJ, et al: Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 106:4254-4259, 2009
33. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
34. Korkaya H, Wicha MS: HER-2, notch, and breast cancer stem cells: Targeting an axis of evil. Clin Cancer Res 15:1845-1847, 2009
35. Mariani G, Fasolo A, De Benedictis E, et al: Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93-104, 2009
36. Korkaya H, Paulson A, Iovino F, et al: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120-6130, 2008
37. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004 (Pubitemid 39485684)
38. Korkaya H, Paulson A, Charafe-Jauffret E, et al: Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7:e1000121, 2009
39. Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139-147, 2007 (Pubitemid 46160989)
40. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-348, 2005 (Pubitemid 40692295)
41. Sansone P, Storci G, Giovannini C, et al: P66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 25:807-815, 2007 (Pubitemid 46354241)
42. Inoue K, Slaton JW, Eve BY, et al: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119, 2000 (Pubitemid 30305111)
43. Inoue K, Okabe S, Sueoka E, et al: The role of interleukin-6 in inhibition of lung metastasis in subcutaneous tumor-bearing mice. Oncol Rep 7:69-73, 2000
44. Sansone P, Storci G, Tavolari S, et al: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988-4002, 2007 (Pubitemid 350224108)
45. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49:2129-2138, 2007
46. Jiralerspong S, Angulo AM, Hung MC: Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer? Cell Cycle 8:2681, 2009
47. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
48. Pierce BL, Ballard-Barbash R, Bernstein L, et al: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437-3444, 2009
49. Kochhar RKV, Bejjanki H, Caldito G, et al: Statins reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol 23:6s, 2005 (suppl; abstr 514)
50. Ridker PM: C-reactive protein, inflammation, and cardiovascular disease: Clinical update. Tex Heart Inst J 32:384-386, 2005
51. Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. New Engl J Med 352:20-28, 2005 (Pubitemid 40075677)
52. Kastritis E, Charidimou A, Varkaris A, et al: Targeted therapies in multiple myeloma. Target Oncol 4:23-36, 2009
53. Huff CA, Matsui W, Smith BD, et al: The paradox of response and survival in cancer therapeutics. Blood 107:431-434, 2006 (Pubitemid 43076361)
54. Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle 4:1693-1698, 2005
55. Theodoropoulos PA, Polioudaki H, Agelaki S, et al: Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288:99-106, 2010
56. Paik S, Kim C, Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409-1411, 2008 (Pubitemid 351468442)
57. Magnifico A, Albano L, Campaner S, et al: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are trastuzumab sensitive. Clinical Cancer Res (in press)
58. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715, 2008 (Pubitemid 351636299)
59. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273, 2009